These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 17522183)

  • 1. Challenges and opportunities of trapping ligands.
    Szkudlinski MW
    Mol Pharmacol; 2007 Aug; 72(2):231-4. PubMed ID: 17522183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trapping of a nonpeptide ligand by the extracellular domains of the gonadotropin-releasing hormone receptor results in insurmountable antagonism.
    Kohout TA; Xie Q; Reijmers S; Finn KJ; Guo Z; Zhu YF; Struthers RS
    Mol Pharmacol; 2007 Aug; 72(2):238-47. PubMed ID: 17409285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overlapping, nonidentical binding sites of different classes of nonpeptide antagonists for the human gonadotropin-releasing hormone receptor.
    Betz SF; Reinhart GJ; Lio FM; Chen C; Struthers RS
    J Med Chem; 2006 Jan; 49(2):637-47. PubMed ID: 16420049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a thieno[2,3-d]pyrimidine-2,4-dione bearing a p-methoxyureidophenyl moiety at the 6-position: a highly potent and orally bioavailable non-peptide antagonist for the human luteinizing hormone-releasing hormone receptor.
    Sasaki S; Cho N; Nara Y; Harada M; Endo S; Suzuki N; Furuya S; Fujino M
    J Med Chem; 2003 Jan; 46(1):113-24. PubMed ID: 12502365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetics of nonpeptide antagonist binding to the human gonadotropin-releasing hormone receptor: Implications for structure-activity relationships and insurmountable antagonism.
    Sullivan SK; Hoare SR; Fleck BA; Zhu YF; Heise CE; Struthers RS; Crowe PD
    Biochem Pharmacol; 2006 Sep; 72(7):838-49. PubMed ID: 16930559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of the hypothalamic-pituitary-gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: studies in human GnRH receptor knock-in mice.
    Nakata D; Masaki T; Tanaka A; Yoshimatsu M; Akinaga Y; Asada M; Sasada R; Takeyama M; Miwa K; Watanabe T; Kusaka M
    Eur J Pharmacol; 2014 Jan; 723():167-74. PubMed ID: 24333551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extracellular loop 3 (EL3) and EL3-proximal transmembrane helix 7 of the mammalian type I and type II gonadotropin-releasing hormone (GnRH) receptors determine differential ligand selectivity to GnRH-I and GnRH-II.
    Li JH; Choe H; Wang AF; Maiti K; Wang C; Salam A; Chun SY; Lee WK; Kim K; Kwon HB; Seong JY
    Mol Pharmacol; 2005 Apr; 67(4):1099-110. PubMed ID: 15635044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2-phenyl-4-piperazinylbenzimidazoles: orally active inhibitors of the gonadotropin releasing hormone (GnRH) receptor.
    Pelletier JC; Chengalvala M; Cottom J; Feingold I; Garrick L; Green D; Hauze D; Huselton C; Jetter J; Kao W; Kopf GS; Lundquist JT; Mann C; Mehlmann J; Rogers J; Shanno L; Wrobel J
    Bioorg Med Chem; 2008 Jul; 16(13):6617-40. PubMed ID: 18511284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. G protein-coupled receptor trafficking in health and disease: lessons learned to prepare for therapeutic mutant rescue in vivo.
    Conn PM; Ulloa-Aguirre A; Ito J; Janovick JA
    Pharmacol Rev; 2007 Sep; 59(3):225-50. PubMed ID: 17878512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and evaluation of homo-bivalent GnRHR ligands.
    Bonger KM; van den Berg RJ; Heitman LH; IJzerman AP; Oosterom J; Timmers CM; Overkleeft HS; van der Marel GA
    Bioorg Med Chem; 2007 Jul; 15(14):4841-56. PubMed ID: 17517510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allosteric and orthosteric binding modes of two nonpeptide human gonadotropin-releasing hormone receptor antagonists.
    Sullivan SK; Brown MS; Gao Y; Loweth CJ; Lio FM; Crowe PD; Struthers RS; Betz SF
    Biochemistry; 2006 Dec; 45(51):15327-37. PubMed ID: 17176055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular evolution of neuropeptide receptors with regard to maintaining high affinity to their authentic ligands.
    Cho HJ; Acharjee S; Moon MJ; Oh DY; Vaudry H; Kwon HB; Seong JY
    Gen Comp Endocrinol; 2007; 153(1-3):98-107. PubMed ID: 17286976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GnRHs and GnRH receptors.
    Millar RP
    Anim Reprod Sci; 2005 Aug; 88(1-2):5-28. PubMed ID: 16140177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. G protein-coupled receptors of the hypothalamic-pituitary-gonadal axis: a case for Gnrh, LH, FSH, and GPR54 receptor ligands.
    Heitman LH; Ijzerman AP
    Med Res Rev; 2008 Nov; 28(6):975-1011. PubMed ID: 18561294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of novel 68Ga- and 18F-labeled GnRH-I analogues with high GnRHR-targeting efficiency.
    Schottelius M; Berger S; Poethko T; Schwaiger M; Wester HJ
    Bioconjug Chem; 2008 Jun; 19(6):1256-68. PubMed ID: 18510351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pro7.33(303) of the human GnRH receptor regulates selective binding of mammalian GnRH.
    Fromme BJ; Katz AA; Millar RP; Flanagan CA
    Mol Cell Endocrinol; 2004 Apr; 219(1-2):47-59. PubMed ID: 15149726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amiloride derivatives and a nonpeptidic antagonist bind at two distinct allosteric sites in the human gonadotropin-releasing hormone receptor.
    Heitman LH; Ye K; Oosterom J; Ijzerman AP
    Mol Pharmacol; 2008 Jun; 73(6):1808-15. PubMed ID: 18344315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress in Clinical Research on Gonadotropin-Releasing Hormone Receptor Antagonists for the Treatment of Prostate Cancer.
    Liu YF; Fu SQ; Yan YC; Gong BB; Xie WJ; Yang XR; Sun T; Ma M
    Drug Des Devel Ther; 2021; 15():639-649. PubMed ID: 33623372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Species selectivity of nonpeptide antagonists of the gonadotropin-releasing hormone receptor is determined by residues in extracellular loops II and III and the amino terminus.
    Reinhart GJ; Xie Q; Liu XJ; Zhu YF; Fan J; Chen C; Struthers RS
    J Biol Chem; 2004 Aug; 279(33):34115-22. PubMed ID: 15155770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of the binding mode of thienopyrimidinedione antagonists to the human gonadotropin releasing hormone receptor using structure-activity relationships, site-directed mutagenesis, and homology modeling.
    Betz SF; Lio FM; Gao Y; Reinhart GJ; Guo Z; Mesleh MF; Zhu YF; Struthers RS
    J Med Chem; 2006 Oct; 49(21):6170-6. PubMed ID: 17034124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.